hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06292377 id: BRUFAST briefTitle: Better Understanding of Fatigue After STroke overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-03-01 date: 2026-03-01 date: 2024-03-05 date: 2024-03-05 name: Brugmann University Hospital class: OTHER briefSummary: Stroke is worldwide the second most common cause of death following heart attack and the leading cause of disability. Post-stroke fatigue (PSF) is a common complication after stroke and can be defined as 'an overwhelming exhaustion or tiredness, not related to exertion, which does not typically improve with rest'. Fatigue following stroke can be divided into early (\< 3 months) and late (\> 3 months) fatigue. PSF can have a considerable impact on a person's everyday activities and quality of life, participation in the rehabilitation process and levels of caregiver burden. Yet no efficient treatment exists to prevent or cure PSF because the pathophysiology remains unclear and seems to be multifaceted.
Autonomic dysfunction is a common complication after stroke, associated with higher morbidity and mortality. An easy tool to measure the function of the autonomic nervous system (ANS) is heart rate variability (HRV), which is defined as the beat-to-beat variation of the heart rate (= interbeat interval (IBI)). It is the result of alterations in the sympathetic and parasympathetic nervous system. In recent systematic reviews, authors stipulate that HRV can be regarded as a prognostic factor for short- and long-term stroke outcomes. HRV can be derived from 24 hours, 5 minutes (short-term) and \< 5 minutes (ultra-short-term) measurements by applying time-domain and frequency-domain indices.
Cardiac complications after acute ischemic stroke (AIS), such as arrhythmias, cardiac dysfunction and myocardial injury, are frequent. The so-called 'stroke-heart syndrome', a concept introduced in 2018, describes a broad spectrum of cardiac changes observed in 10-20% of patients with AIS within the first month after stroke onset, with a peak in the first 72 hours. A dysregulation in the neural-cardiac control after stroke is suspected to be the cause of the cascade leading to cardiac complications, in which autonomic dysfunction and inflammation seem to be part of the underlying mechanism.
* the role of pre-existing fatigue + pre-existing or post-stroke newly diagnosed cognitive impairment, depression and sleep disturbances on the course of PSF. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 250 type: ESTIMATED name: ECG name: Transthoracic echography (TTE) name: Blood sampling measure: Heart rate variability (HRV) measure: Heart rate variability (HRV) measure: Heart rate variability (HRV) measure: Transthoracic echography (TTE) measure: Transthoracic echography (TTE) measure: Transthoracic echography (TTE) measure: Fatigue Severity Scale measure: Fatigue Severity Scale measure: Fatigue Severity Scale measure: N-terminal pro-brain natriuretic peptide (NT-proBNP) measure: N-terminal pro-brain natriuretic peptide (NT-proBNP) measure: N-terminal pro-brain natriuretic peptide (NT-proBNP) measure: cardiac troponin (cTnT) measure: Blood CRP level measure: Blood neutrophil-to-lymphocyte ratio (NLR) measure: Stroke localization in the brain measure: Fazekas scale measure: Global cortical atrophy scale measure: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) measure: Presence for pre-existing fatigue (yes/no) measure: Duration of pre-existing fatigue measure: Patient Health Questionnaire-2 (PHQ-2) measure: Patient Health Questionnaire-2 (PHQ-2) measure: Patient Health Questionnaire-2 (PHQ-2) measure: Montreal Cognitive Assessment (MoCA) questionnaire measure: Montreal Cognitive Assessment (MoCA) score measure: Insomnia Severity Index (ISI) measure: Insomnia Severity Index (ISI) measure: Insomnia Severity Index (ISI) measure: Complete blood count abnormalities: yes/no measure: Renal insufficiency: yes/no measure: Electrolyte imbalance: yes/no measure: Abnormal liver enzymes: yes/no measure: Dyslipidemia: yes/no measure: Diabetes: yes/no measure: Thyroid disorder: yes/no measure: Iron deficiency: yes/no sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Brugmann city: Brussels zip: 1020 country: Belgium name: Anissa OURTANI, MD role: CONTACT phone: 024754819 email: Anissa.OURTANI@chu-brugmann.be name: Anissa OURTANI role: PRINCIPAL_INVESTIGATOR lat: 50.85045 lon: 4.34878 facility: UZ Brussel city: Brussel zip: 1090 country: Belgium name: Sylvie De Raedt, MD role: CONTACT email: Sylvie.DeRaedt@uzbrussel.be name: Sylvie De Raedt role: PRINCIPAL_INVESTIGATOR lat: 50.85045 lon: 4.34878 hasResults: False
nctId: NCT06292364 id: PGIDS/BHRC/23/106 briefTitle: Comparison of Retention Characteristics of Immediate vs Delayed Retainer Delivery Using 3D Digital Model Analysis overallStatus: RECRUITING date: 2023-11-05 date: 2024-11-05 date: 2024-12-05 date: 2024-03-05 date: 2024-03-05 name: Postgraduate Institute of Dental Sciences Rohtak class: OTHER briefSummary: Retention has been defined as "the holding of teeth following orthodontic treatment in the treated position for the period of time necessary for the maintenance of the result". Controversies regarding retention regime exist due to lack of high quality evidence regarding duration, type and timing of different type retainer.The present randomised controlled trial will be undertaken to assess the changes and compare if there is any difference in movement of teeth in post orthodontic treatment cases with immediate and delayed (post 7 days) delivery using beggs retainer and change in level of bone biomarker over 6 months period of retention . conditions: Relapse studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: immediate orthodontic retainer delivery name: delayed orthodontic retainer delivery measure: overjet measure: overjet measure: overjet measure: Overjet measure: contact point displacement measure: contact point displacement measure: contact point displacement measure: contact point displacement measure: overbite measure: overbite measure: overbite measure: overbite measure: intermolar width measure: intermolar width measure: intermolar width measure: intermolar width measure: intercanine width measure: intercanine width measure: intercanine width measure: intercanine width measure: GCF - elisa measure: GCF - elisa measure: GCF - elisa measure: GCF - elisa sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Pgids Rohtak status: RECRUITING city: Rohtak state: Haryana zip: 124001 country: India name: Dr. Rekha Sharma, MDS role: CONTACT phone: 8076190296 email: rajsringari@gmail.com lat: 28.89447 lon: 76.58917 hasResults: False
nctId: NCT06292338 id: AUCHAU briefTitle: Lung Sonar in Neonatal Respiratory Disorders overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-05-01 date: 2024-03-05 date: 2024-03-05 name: Gehad Adel Mohammed Hussein class: OTHER briefSummary: This study aimed to determine the value of chest ultrasonography in comparison to other tools as chest x-ray and ABG in diagnosis and follow up of neonates with respiratory disorders. conditions: Neonatal Respiratory Distress studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 1 type: ESTIMATED measure: Comparing between LUS and Chest xRay in neonatal respiratory disorders assessment sex: ALL minimumAge: 1 Day maximumAge: 28 Days stdAges: CHILD hasResults: False
nctId: NCT06292325 id: FDG_88-17 briefTitle: Psychological Aspects in OSA acronym: PSICOSA overallStatus: ENROLLING_BY_INVITATION date: 2023-05-08 date: 2023-05-08 date: 2024-05-31 date: 2024-03-05 date: 2024-03-07 name: Fondazione Don Carlo Gnocchi Onlus class: OTHER name: Catholic University of the Sacred Heart briefSummary: The research project consists of an observational study. Obstructive Sleep Apnea (OSA) is a condition characterized by recurrent episodes of upper airway collapse during sleep, leading to decreased blood oxygen levels and disruptions of normal sleep patterns. Estimates of its prevalence vary, but its impact on patients' quality of life is evident.
The research aims to explore the perception and awareness of the disease and its impact on the individual and couple's lives of patients with OSA and their bed partners, to assess patients' perceptions of the disease and symptoms, as well as their bed partners' perceptions. Moreover, psychological aspects of living with OSA, such as perceived stress, depression, anxiety, sleep quality, daily sleepiness will be studied to observe the association with Continuous Positive Airway Pressure (CPAP) adherence. conditions: Osa Syndrome studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 246 type: ESTIMATED name: Continuous Positive Airway Pressure (CPAP) measure: Brief Illness Perception Questionnaire (Brief IPQ) measure: CPAP therapy adherence (hours/night) measure: Dyadic Adjustment Scale (DAS) measure: The experience in close relationships-revised (ECR-R) Scale measure: The Psychological General Well-Being Index (PGWB-S) measure: The Patient Health Questionnaire - 9 (PHQ-9) measure: The Generalized Anxiety Scale -7 (GAD-7) measure: The Mannheim Dream Questionnaire (MADRE) measure: The EP worth scale (ESS) measure: Pittsburgh Sleep Quality Index (PSQI) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Fondazione Don Carlo Gnocchi city: Milan state: MI zip: 20148 country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06292312 id: 19.12.2023/10-483 briefTitle: Investigation of the Effectiveness of Craniosacral Therapy in Patients With Multiple Sclerosis. overallStatus: RECRUITING date: 2024-02-27 date: 2025-04-15 date: 2025-05-15 date: 2024-03-05 date: 2024-03-05 name: Ankara Yildirim Beyazıt University class: OTHER name: Lokman Hekim Üniversitesi briefSummary: Although the cause of Multiple Sclerosis (MS), one of the common demyelinating diseases of the central nervous system, has not yet been fully elucidated, autonomic nervous system dysfunction has been suggested in its etiology. Symptoms such as fatigue, problems with bladder, bowel, cardiovascular, sleep, sexual and sweating functions, abnormal sympathetic skin response or decreased heart rate variation support this hypothesis.
In the treatment of many neurological diseases such as Multiple Sclerosis, complementary medicine practices and non-traditional therapies have recently been shown to be effective in addition to conventional practices. One of these practices, craniosacral therapy (CST), uses manual palpation and manipulation of the craniosacral system to influence sensory, motor, cognitive and emotional processes in the nervous system. In addition, it is thought that applying external force to certain bone elements can have a positive effect on various symptoms in patients with MS, based on the knowledge that it can be transmitted within the system. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: dual parallel group design primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Single (outcomes assesor) The evaluation of the patients will be carried out by a blinded investigator. whoMasked: OUTCOMES_ASSESSOR count: 32 type: ESTIMATED name: Craniosacral therapy name: Conventional physiotherapy measure: Dynamic posturography measure: Heart rate variability measure: Pain level measure: Central sensitization measure: Fatigue measure: Sleep quality measure: Life quality sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Yıldırım Beyazıt University status: RECRUITING city: Ankara zip: 06010 country: Turkey name: Hilal Aslan role: CONTACT phone: 05372565397 email: hilalaslan@aybu.edu.tr lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06292299 id: INGN22RM471P id: 10072600 type: OTHER_GRANT domain: PneumoWave Ltd & Innovate UK briefTitle: The PARS Study: Paediatric Advanced Respiratory Service Study - An Observational Diagnostic Feasibility Study acronym: PARS overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-12 date: 2025-12 date: 2024-03-05 date: 2024-03-05 name: NHS Greater Clyde and Glasgow class: OTHER name: INNOVATEUK briefSummary: Diagnostic investigations in paediatric respiratory and sleep medicine are often challenging due to patient size (due to prematurity), tolerability, and compliance with "gold standard equipment". Children with sensory/behavioural issues, at increased risk of sleep disordered breathing (SDB), often find tolerating standard diagnostic equipment difficult. There is a need to develop non-invasive, wireless, devices designed for the paediatric population. Devices must address health in-equalities as high-risk children, with low birth weights, genetic syndromes, or complex neuro-disabilities, are often unable to undergo current investigations, particularly in sleep medicine. Prompt and accurate diagnosis of SDB is important to facilitate early intervention and improve outcomes
Infants in the neonatal period can have immature breathing control which manifests as excessive central breathing pauses, apnoea's, whilst asleep requiring oxygen therapy. There is also a risk to newborn term infants of sudden unexpected neonatal collapse, even in "low risk" babies. Diagnosis of breathing issues in babies can be challenging since babies are often too small for standard monitoring equipment. Effective monitoring and appropriate treatment of apnoea's has been shown to improve prognosis in terms of 5-year mortality and neurodevelopmental outcomes.
This observational study is part of a phased clinical program of research that aims to validate a small wearable biosensor developed by PneumoWave Ltd in a paediatric clinical setting with the overall primary endpoints of monitoring and assessing respiratory pattern as an aid to sleep diagnostics, and as a device to monitor apnoea in neonatal patients. conditions: Sleep Disordered Breathing conditions: Apnea of Prematurity conditions: Respiratory Rate studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Pneumowave measure: Assess the feasibility of collecting respiratory waveform data using Pneumowave device in patients who have (1) attended the sleep laboratory for CR- polysomnography and (2) are inpatient in neonatal unit measure: Collate respiratory data in patients who have attended the sleep laboratory for CR- poly or inpatient in neonatal unit. Respiratory data will observe: (1) Normal respiratory effort (2) Response to treatments measure: Collate waveform and motion artefact data in patients who have attended overnight CR-polysomnography measure: Collate waveform and motion artefact data in neonatal patients at risk of central apnoea measure: Assess the useability of Pneumowave in the opinion of the clinician, nurse and patient sex: ALL minimumAge: 1 Minute maximumAge: 16 Years stdAges: CHILD facility: Royal Hospital for Children, Glasgow city: Glasgow state: Glasgow City zip: G51 4TF country: United Kingdom name: Ross J Langley, MBChB BSc PhD MRCPCH role: CONTACT phone: 0141 451 6582 email: ross.langley@ggc.scot.nhs.uk name: Hannah Vennard, MBChB BMSc role: CONTACT phone: 0141 451 6582 email: hannah.vennard@ggc.scot.nhs.uk lat: 55.86515 lon: -4.25763 facility: Royal Hospital for Children, Glasgow city: Glasgow zip: G51 4TF country: United Kingdom lat: 55.86515 lon: -4.25763 hasResults: False
nctId: NCT06292286 id: UW 22-704 briefTitle: Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer acronym: SCENIC overallStatus: RECRUITING date: 2023-11-01 date: 2025-12-31 date: 2026-07-01 date: 2024-03-05 date: 2024-03-05 name: The University of Hong Kong class: OTHER briefSummary: About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known. conditions: Recurrent Ovarian Carcinoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Neoadjuvant carboplatin and paclitaxel followed by cytoreductive surgery primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: Carboplatin or cisplatin name: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar name: Bevacizumab or biosimilar name: Cytoreductive surgery measure: Complete resection rate measure: 12-month progression-free survival rate measure: 12-month overall survival rate measure: Surgical complication rate measure: Quality of life scale sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The University of Hong Kong status: RECRUITING city: Hong Kong country: Hong Kong name: Lesley Lau role: CONTACT phone: 852-22554518 name: Ka Yu Tse role: CONTACT phone: 852-22554265 email: tseky@hku.hk name: Ka Yu Tse, MBBS, PhD role: PRINCIPAL_INVESTIGATOR lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06292273 id: ANET19 briefTitle: Bupivacaine With Dexmedetomidine Versus Bupivacaine Alone for Transversus Abdominis Plane Block in Caesarean Section overallStatus: COMPLETED date: 2023-10-10 date: 2024-02-01 date: 2024-02-20 date: 2024-03-05 date: 2024-03-05 name: Menoufia University class: OTHER briefSummary: Transversus Abdominis plane (TAP) block is a regional technique for providing analgesia of the anterolateral abdominal wall. TAP block are commonly given in patients who have undergone various abdominal as well as pelvic surgeries such as caesarean section, hysterectomy, appendicectomy and various laparoscopic surgeries. this study is conducted to analyse the effect of addition of dexmedetomidine to bupivacaine in Transversus Abdominis Plane (TAP) block. conditions: Post Operative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized, double blind case control primaryPurpose: PREVENTION masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: Transversus Abdominis Plane Block with bupivacain Plus dexamethasone name: Transversus Abdominis Plane Block with bupivacain measure: Post operative pain measure: Sedation measure: Heart rate measure: Total analgesic consumption measure: Side effects sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Faculty of Medicine Menoufia University city: Cairo state: Governorate zip: 32511 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06292260 id: 2020-2054-2 briefTitle: Digital Toolkit for Skin Diseases in LMICs: Part 2 acronym: MIND-the-SKIN2 overallStatus: RECRUITING date: 2024-03-18 date: 2026-05-31 date: 2026-05-31 date: 2024-03-05 date: 2024-04-17 name: Tulane University class: OTHER name: Hope Commission International name: Institut Pasteur of Cote d'Ivoire name: Institut Raoul Follereau name: Centre Suisse de Recherches Scientifiques en Cote d'Ivoire name: Tokyo Medical and Dental University briefSummary: Impact evaluation of eSkinHealth in improving case detection of skin NTDs and treatment outcomes in rural and urban settings conditions: Skin Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 1000 type: ESTIMATED name: mHealth app measure: Number of cases of each skin NTD (neglected tropical disease) and other skin conditions as compared to the pre-intervention measure: Case confirmation rate for each skin NTD (neglected tropical disease) and other skin conditions by dermatologists measure: Number of days from registry to confirmatory diagnosis measure: Feasibility, usability, and effectiveness of the surveillance approach using eSkinHealth app measure: Capacity building and effectiveness of training sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hope Commission International status: RECRUITING city: Abidjan country: Côte D'Ivoire name: Aubin Yao, MS role: CONTACT email: aubin@hopecommission.org name: Eric-Herman N'da Kouakou role: CONTACT email: ekouakou@hopecommission.org name: Bamba Vagamon, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 5.30966 lon: -4.01266 hasResults: False
nctId: NCT06292247 id: A0503023 briefTitle: Effectiveness of CBT and APT on Managing Child Anxiety in Dental Office overallStatus: ACTIVE_NOT_RECRUITING date: 2023-06-01 date: 2023-10-23 date: 2024-05-01 date: 2024-03-05 date: 2024-03-07 name: Mansoura University class: OTHER briefSummary: This study was conducted to the Effectiveness of Cognitive Behavioral Therapy and Auricular Plaster Therapy on Managing Child Anxiety in Dental Office. conditions: Dental Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Group 1 (CBT) Group 2 (APT) Group3 (control TSD) primaryPurpose: OTHER masking: NONE count: 60 type: ESTIMATED name: Cognitive behavioral therapy name: Auricular plaster therapy name: Tell Show Do measure: Venham Clinical Anxiety Scale measure: Heart Rate to detect the anxiety. measure: RMS-Self Pictorial scale to detect the anxiety. measure: Parental acceptance of the behavior management technique sex: ALL minimumAge: 4 Years maximumAge: 7 Years stdAges: CHILD facility: Faculty of dentistry city: Mansoura state: Dakahlia zip: 35511 country: Egypt lat: 31.03637 lon: 31.38069 hasResults: False
nctId: NCT06292234 id: OMFS briefTitle: Patient Specific Implant Versus Miniplates for Advancement of Hypoplastic Maxilla overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-02-01 date: 2025-03-01 date: 2024-03-05 date: 2024-04-19 name: Cairo University class: OTHER briefSummary: Distraction osteogenesis is the treatment of choice in management of severe maxillary anteroposterior deficiency allowing for a progressive bone generation and simultaneous expansion of the surrounding scarred soft tissue \& better long-term stability \& less relapse rate. conditions: Cleft Lip and Palate studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel randomized controlled trial with 1:1 allocation ratio and superiority framework primaryPurpose: TREATMENT masking: SINGLE maskingDescription: single blinded clinical trial whoMasked: PARTICIPANT count: 20 type: ESTIMATED name: PSI name: Conventional miniplates measure: Distraction effectiveness measure: Velopharyngeal insufficiency measure: Speech measure: Operative time measure: Wound dehiscence measure: Infection measure: Nerve affection measure: Screw loosening measure: Overall complications sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT hasResults: False